Evidence map›Paper›PMID 39893413›Full record

ArticleBMC musculoskeletal disorders2025

The association of lipids and novel non-statin lipid-lowering drug target with osteoporosis: evidence from genetic correlations and Mendelian randomization.

Qingcong Zheng, Rongjie Lin, Du Wang, Rongsheng Chen, Weihong Xu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC musculoskeletal disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Qingcong Zheng *Department of Spinal Surgery, the First Affiliated Hospital of Fujian Medical University, Fuzhou, 350004, China.
Rongjie Lin *Department of Orthopedic Surgery, Fujian Medical University Union Hospital, Fuzhou, 350001, China.
Du Wang *Arthritis Clinical and Research Center, Peking University People's Hospital, Beijing, 100044, China.
Rongsheng ChenDepartment of Spinal Surgery, the First Affiliated Hospital of Fujian Medical University, Fuzhou, 350004, China. rongshengc@126.com.
Weihong XuDepartment of Spinal Surgery, the First Affiliated Hospital of Fujian Medical University, Fuzhou, 350004, China. xuweihong815@126.com.

Funding

the Natural Science Foundation of Fujian Province 2021J02035
6 · The paper itself

Abstract

backgroundIt remains controversial whether lipids affect osteoporosis (OP) or bone mineral density (BMD), and causality has not been established. This study aimed to investigate the genetic associations between lipids, novel non-statin lipid-lowering drug target genes, and OP and BMD.

methodsMendelian randomization (MR) method was used to explore the genetic associations between 179 lipid species and OP, BMD. Drug-target MR analysis was used to explore the causal associations between angiopoietin-like protein 3 (ANGPTL3) and apolipoprotein C3 (APOC3) inhibitors on BMD.

resultsThe IVW results with Bonferroni correction indicated that triglyceride (TG) (51:3) (OR = 1.0029; 95% CI: 1.0014-1.0045; P = 0.0002) and TG (56:6) (OR = 1.0021; 95% CI: 1.0008-1.0033; P = 0.0011) were associated with an increased risk of OP; TG (51:2) (OR = 0.9543; 95% CI: 0.9148-0.9954; P = 0.0298) was associated with decreased BMD; and ANGPTL3 inhibitor (OR = 1.1342; 95% CI: 1.0393-1.2290; P = 0.0093) and APOC3 inhibitor (OR = 1.0506; 95% CI: 1.0155-1.0857; P = 0.0058) was associated with increased BMD.

conclusionsMR analysis indicated causal associations between genetically predicted TGs and OP and BMD. Drug-target MR analysis showed that ANGPTL3 and APOC3 have the potential to serve as novel non-statin lipid-lowering drug targets to treat or prevent OP.

Indexed as

Apolipoprotein C-IIIBone DensityHypolipidemic AgentsLipidsOsteoporosisAngiopoietin-Like Protein 3Angiopoietin-like ProteinsFemaleGenetic Association StudiesHumansMendelian Randomization AnalysisPolymorphism, Single NucleotideTriglyceridesAngiopoietin-Like Protein 3Angiopoietin-like ProteinsANGPTL3 protein, humanAPOC3 protein, humanApolipoprotein C-IIIHypolipidemic AgentsLipidsTriglyceridesANGPTL3APOC3Bone mineral densityDrug target Mendelian randomizationLipidsOsteoporosis

Identifiers

PMID39893413
PMCPMC11787747

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.